额外的全外体序列测序对面板序列测序的临床益处在一个全新的现实世界的分子瘤板上

E Krieghoff-Henning1, T Michaeli2, T Boch3

  • 1Department of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.

ESMO open
|November 26, 2025
PubMed
概括

全外体测序 (WES) 为晚期癌症患者提供了额外的可操作的治疗建议,特别是复杂的生物标志物. 需要进一步的前性研究来确认WES对单独面板测序的好处.

相关概念视频